INTRODUCTION: Overexpression of the Polycomb repressive complex 2 (PRC2) subunit Enhancer of Zeste 2 (EZH2) occurs in several malignancies, including prostate cancer, breast cancer, medulloblastoma, and glioblastoma multiforme. Recent evidence suggests that EZH2 may also have a role in rhabdoid tumors. Atypical teratoid/rhabdoid tumor (ATRT) is a rare, high-grade embryonal brain tumor that occurs most commonly in young children and carries a very poor prognosis. ATRTs are characterized by absence of the chromatin remodeling protein SMARCB1. Given the role of EZH2 in regulating epigenetic changes, we investigated the role of EZH2 in ATRT. METHODS: Microarray analysis was used to evaluate expression of EZH2 in ATRT tumor samples. We used shRNA and a chemical inhibitor of EZH2 to examine the impact of EZH2 inhibition on cell growth, proliferation, and tumor cell self-renewal. RESULTS: Here, we show that targeted disruption of EZH2 by RNAi or pharmacologic inhibition strongly impairs ATRT cell growth, suppresses tumor cell self-renewal, induces apoptosis, and potently sensitizes these cells to radiation. Using functional analysis of transcription factor activity, we found the cyclin D1-E2F axis to be repressed after EZH2 depletion in ATRT cells. CONCLUSIONS: Our observations provide evidence that EZH2 disruption alters cell cycle progression and may be an important new therapeutic target, particularly in combination with radiation, in ATRT.
INTRODUCTION: Overexpression of the Polycomb repressive complex 2 (PRC2) subunit Enhancer of Zeste 2 (EZH2) occurs in several malignancies, including prostate cancer, breast cancer, medulloblastoma, and glioblastoma multiforme. Recent evidence suggests that EZH2 may also have a role in rhabdoid tumors. Atypical teratoid/rhabdoid tumor (ATRT) is a rare, high-grade embryonal brain tumor that occurs most commonly in young children and carries a very poor prognosis. ATRTs are characterized by absence of the chromatin remodeling protein SMARCB1. Given the role of EZH2 in regulating epigenetic changes, we investigated the role of EZH2 in ATRT. METHODS: Microarray analysis was used to evaluate expression of EZH2 in ATRT tumor samples. We used shRNA and a chemical inhibitor of EZH2 to examine the impact of EZH2 inhibition on cell growth, proliferation, and tumor cell self-renewal. RESULTS: Here, we show that targeted disruption of EZH2 by RNAi or pharmacologic inhibition strongly impairs ATRT cell growth, suppresses tumor cell self-renewal, induces apoptosis, and potently sensitizes these cells to radiation. Using functional analysis of transcription factor activity, we found the cyclin D1-E2F axis to be repressed after EZH2 depletion in ATRT cells. CONCLUSIONS: Our observations provide evidence that EZH2 disruption alters cell cycle progression and may be an important new therapeutic target, particularly in combination with radiation, in ATRT.
Authors: Diane K Birks; Andrew M Donson; Purvi R Patel; Christopher Dunham; Andrea Muscat; Elizabeth M Algar; David M Ashley; B K Kleinschmidt-Demasters; Rajeev Vibhakar; Michael H Handler; Nicholas K Foreman Journal: Neuro Oncol Date: 2011-09-23 Impact factor: 12.300
Authors: F Orzan; S Pellegatta; P L Poliani; F Pisati; V Caldera; F Menghi; D Kapetis; C Marras; D Schiffer; G Finocchiaro Journal: Neuropathol Appl Neurobiol Date: 2011-06 Impact factor: 8.090
Authors: João D Pereira; Stephen N Sansom; James Smith; Marc-Werner Dobenecker; Alexander Tarakhovsky; Frederick J Livesey Journal: Proc Natl Acad Sci U S A Date: 2010-08-23 Impact factor: 11.205
Authors: Susan N Chi; Mary Ann Zimmerman; Xiaopan Yao; Kenneth J Cohen; Peter Burger; Jaclyn A Biegel; Lucy B Rorke-Adams; Michael J Fisher; Anna Janss; Claire Mazewski; Stewart Goldman; Peter E Manley; Daniel C Bowers; Anne Bendel; Joshua Rubin; Christopher D Turner; Karen J Marcus; Liliana Goumnerova; Nicole J Ullrich; Mark W Kieran Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: Michiel Smits; Jonas Nilsson; Shahryar E Mir; Petra M van der Stoop; Esther Hulleman; Johanna M Niers; Phillip C de Witt Hamer; Victor E Marquez; Jacqueline Cloos; Anna M Krichevsky; David P Noske; Bakhos A Tannous; Thomas Würdinger Journal: Oncotarget Date: 2010-12
Authors: Stephen C Mack; Christopher G Hubert; Tyler E Miller; Michael D Taylor; Jeremy N Rich Journal: Nat Neurosci Date: 2016-01 Impact factor: 24.884
Authors: Hiroaki Katagi; Nundia Louis; Dusten Unruh; Takahiro Sasaki; Xingyao He; Ali Zhang; Quanhong Ma; Andrea Piunti; Yosuke Shimazu; Jonathan B Lamano; Angel M Carcaboso; Xiao Tian; Andrei Seluanov; Vera Gorbunova; Kathryn L Laurie; Akihide Kondo; Nitin R Wadhwani; Rishi Lulla; Stewart Goldman; Sriram Venneti; Oren J Becher; Lihua Zou; Ali Shilatifard; Rintaro Hashizume Journal: Clin Cancer Res Date: 2019-06-21 Impact factor: 12.531
Authors: Khaled Elsayad; Jan Kriz; Laith Samhouri; Uwe Haverkamp; Ronald Straeter; Walter Stummer; Hans Theodor Eich Journal: Strahlenther Onkol Date: 2016-06-07 Impact factor: 3.621
Authors: Michael C Frühwald; Jaclyn A Biegel; Franck Bourdeaut; Charles W M Roberts; Susan N Chi Journal: Neuro Oncol Date: 2016-01-10 Impact factor: 12.300
Authors: F Volpin; J Casaos; J Sesen; A Mangraviti; J Choi; N Gorelick; J Frikeche; T Lott; R Felder; S J Scotland; T S K Eisinger-Mathason; H Brem; B Tyler; N Skuli Journal: Oncogene Date: 2016-12-12 Impact factor: 9.867
Authors: Roberta Ciarapica; Elena Carcarino; Laura Adesso; Maria De Salvo; Giorgia Bracaglia; Pier Paolo Leoncini; Alessandra Dall'agnese; Federica Verginelli; Giuseppe M Milano; Renata Boldrini; Alessandro Inserra; Stefano Stifani; Isabella Screpanti; Victor E Marquez; Sergio Valente; Antonello Mai; Pier Lorenzo Puri; Franco Locatelli; Daniela Palacios; Rossella Rota Journal: BMC Cancer Date: 2014-02-27 Impact factor: 4.430